ArticlePathology oncology research : POR2026
Delayed diagnostic imaging but stable treatment initiation for kidney cancer during the COVID-19 pandemic: a Hungarian cohort study.
Article in Pathology oncology research : POR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: The COVID-19 pandemic influenced cancer care worldwide, delaying diagnosis and treatment. We compared waiting times - time to initial diagnostic imaging, time to treatment, time to histopathological diagnosis, and length of hospital stay - of kidney cancer patients between pre-COVID-19 and COVID-19 periods at a large regional Hungarian clinical center. We also aimed to identify factors predicting prolonged waiting times. Methods: Data from 400 adult kidney cancer patients (all histologically renal cell carcinoma) at the University of Pécs Urology Clinic were analyzed retrospectively, for two periods (1 January 2019-15 March 2020, pre-pandemic; 16 March 2020-13 May 2021, pandemic). Demographic and clinical characteristics were collected, and time intervals calculated from electronic health records, followed by statistical analyses. Results: Median time from symptom onset to initial diagnostic imaging increased significantly from 7.5 to 34 days during the pandemic (p = 0.026), while time to treatment (p = 0.492), time to histopathological diagnosis (p = 0.575), and length of hospital stay (p = 0.319) remained stable. Median healthcare-related waiting times (time to treatment and time to histopathological diagnosis) were comparatively long (range: 95.5-111 days). Advanced-stage disease (III-IV) was protective for prolonged time to initial diagnostic imaging (OR 0.205, 95% CI 0.074-0.568) pre-pandemic and for prolonged time to histopathological diagnosis (OR 0.496, 95% CI 0.254-0.971) during the pandemic. No other demographic or clinical factors influenced waiting times significantly. Conclusion: The pandemic prolonged the interval from symptom onset to initial diagnostic testing, likely due to fear-driven healthcare avoidance by patients, but did not affect healthcare-related waiting times. Advanced-stage disease predicted shorter waiting times, with variable influence across periods. Our findings highlight the need for patient education and careful prioritization of care, with waiting times exceeding those reported in other international settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.